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Characterisation of a new mouse monoclonal antibody (ONS-M21)
reactive with both medulloblastomas and gliomas
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Department ofNeurosurgery, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565, Japan.
Summary We developed an IgGI mouse monoclonal antibody (ONS-M21) directed against a cell surface
antigen of medulloblastomas and gliomas in immunisation of mice with the ONS-76 medulloblastoma cell line.
The antibody specifically reacted with medulloblastomas, supratentorial primitive neuroectodermal tumours
(SPNETs) and gliomas, but not with other neuroectodermally derived tumours (neuroblastoma and
melanoma) or with other kinds of tumours (meningioma, neurinoma, leukaemia, and small cell lung cancer).
No reactivity was identified with normal body tissues, including peripheral blood cells. Characterisation of the
ONS-M21 antigen showed that it was a trypsin-sensitive glycoprotein with a molecular weight of 80 kDa on
SDS-PAGE. The pattern of reactivity and the biochemical properties of this antigen were different from those
of other markers of medulloblastoma. These results indicate that ONS-M21 detects a new tumour-associated
cell surface antigen specifically expressed by medulloblastomas, SPNETs, and gliomas. This is the first report
that medulloblastomas may share common cell surface antigens with gliomas, although most studies have
concluded that medulloblastoma has a predominantly neuronal phenotype. The lack of reactivity with normal
tissue implies that ONS-M21 has potential applications as both a diagnostic tool and a therapeutic agent.
Medulloblastoma is the most common primitive neuroecto-
dermal tumour (PNET) of the central nervous system in
children (Rorke, 1983; Rorke et al., 1985; Dehner, 1986). The
survival rate of patients with medulloblastoma has increased
over the past four decades due to multiple factors, including
improvement of surgical techniques and postoperative care,
but mainly due to advances in whole-neuroaxis radiotherapy
(Farwell et al., 1984; Hershatter et al., 1986). However, des-
pite the recent advances in the treatment of many other
childhood malignancies by combination chemotherapy, the
long-term prognosis of medulloblastoma is still poor. The
major reason for treatment failure is that recurrent tumours
become insensitive to radiotherapy and chemotherapy (Pas-
tan & Gottesman, 1987). In this situation, a potential new
therapeutic approach is the utilisation of monoclonal
antibodies, as is done for autologous bone marrow transplan-
tation with purged bone marrow (Coombes et al., 1986).
So far, ten monoclonal antibodies (mAbs) directed against
medulloblastomas have been described (Kemshead et al.,
1983; Allan et al., 1983; Jones et al., 1984; Gross et al., 1986;
Wikstrand et al., 1986; Gibson & Kemshead, 1987; Feickert
et al., 1989; Jennings et al., 1989; Takahashi et al., 1990), but
most of these antibodies also show reactivity with a broad
range of other tumours and with normal tissues, making
their in vivo use problematic.
In the present study, we tried to develop mAbs with an
increased specificity for medulloblastoma. Assuming that any
mAb will have some degree of cross-reactivity with normal
tissues, we selected those which at least did not react with
peripheral blood cells or normal brain tissue, thus increasing
the possibility of their future clinical application.
Materials and methods
Cell lines
We used cultured human cell lines that were established from
medulloblastomas and gliomas (Tamura et al., 1989;
Okamoto et al., 1990; Moriuchi et al., 1991). Daoy was
obtained from the American Type Culture Collection and
cultured in the medium suggested by the supplier with 10%
foetal bovine serum (FBS) in a humidified atmosphere of 5%
CO2 at 37'C. In addition, small cell lung cancer cell lines
were kindly provided by Dr I. Tachibana (Department of
Medicine, Osaka University Medical School, Osaka;
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Tachibana et al., 1992), and the other cell lines studied were
obtained from the Japan Cancer Resources Bank. The cells
were maintained in RPMI-1640 medium supplemented with
10% FBS, 2 mM glutamine, and 50Ag ml-' gentamycin. All
cell lines used were free of Mycoplasma and bacterial infec-
tions.
Generation ofmouse monoclonal antibodies
Female BALB/c mice were immunised three times at 10-day
intervals by the intraperitoneal injection of approximately
1 x 107 cells of an established human medulloblastoma cell
line (ONS-76; IFO No. 50355) (Tamura et al., 1989). Three
days after the last injection, two mice were sacrificed and
their spleen cells were electrically fused with P3X63-Ag8,653
(JCRB 0028) myeloma cells (Zimmerman, 1982). Then the
supernatants of culture wells with growing clones were tested
for specific antibodies by an enzyme-linked immunosorbent
assay that assessed reactivity with cell surface antigens using
a screening panel of cultured cell lines derived from medul-
loblastomas, gliomas, neuroblastomas, and other tumours.
The selected clones were subcloned three times by limiting
dilution and were injected intraperitoneally into BALB/c
mice primed with 2,6,10,14-tetramethyl-pentadecane, after
which mAbs were obtained from the ascitic fluid.
The immunoglobulin subclass of the cloned mAb (ONS-
M21), was determined with a mouse mAb isotyping kit
(Amersham, UK), and was shown to be IgGI. Its specificity
was tested by flow cytometry using normal peripheral blood
cells from five healthy individuals and 46 tumour cell lines. It
was also tested by immunohistochemical analysis using 40
samples of human tumours, seven samples of normal adult
brain tissue, five samples of fetal brain tissue (23 or 32 weeks'
gestation), five samples of other normal tissues, and a sample
of reactive astrocytes obtained from around a cerebral
arteriovenous malformation.
Preparation ofnormal andfoetal tissues
Normal tissues were obtained during decompression of the
brain or from the edges of resected at operation. Foetal
tissues were obtained at the time of necropsy after spon-
taneous or legal abortion and were stored frozen at - 80°C
until use.
Flow cytometric analysis
ONS-M21 antigen expression by peripheral white blood
cells Whole blood from healthy individuals was collected
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into heparinised tubes, diluted ten times with phosphate-
buffered saline (PBS), and centrifuged at 300 g for 10min to
obtain the buffy coat. The buffy coat was then diluted to the
original blood volume. Cells (100 tlI) were incubated with
ONS-M21 for 30 min at 4°C, washed twice with PBS, and
then incubated at 4°C for 30 min with fluorescein
isothiocyanate (FITC)-labelled goat anti-mouse IgG (Cappel
Laboratories, Durham, NC). After washing again with PBS,
the cells were incubated at 4°C for 30 min with rhodamine-
conjugated anti-CD3, anti-CD1 lb, or anti-CD16 mAbs
(Beckton-Dickinson, Mountain View, CA). Then the cells
were washed again with PBS, contaminating erythrocytes
were removed with lysis buffer (Beckton-Dickinson, Moun-
tain View, CA), and the cells were analysed by flow
cytometry. Negative controls were incubated with nonim-
mune mouse IgGi (Tago Company, Burlington, CA).
ONS-M21 antigen expression by cultured cells Cultured cells
were washed three times with PBS and incubated with ONS-
M21 for 30 min at 4°C. After incubation, the cells were again
washed three times with PBS and then incubated for 30 min
at 4°C with FITC-labelled goat anti-mouse IgG. Cells
incubated with nonimmune mouse IgG served as the control
for background fluorescence.
Characterisation of the ONS-M21 antigen ONS-76 cells
were fixed with 70% ethanol for 30 min at 4°C. The cells
were separately incubated overnight at 37°C with 0.1% tryp-
sin (Nacalai Tesque, Inc., Kyoto, Japan), 0.1 U ml
neuraminidase (Nacalai Tesque), or PBS, and then were
incubated with ONS-M21 for 60 min at room temperature.
Next, the cells were washed with PBS and incubated with
FITC-labelled goat anti-mouse IgG.
Flow cytometry was performed using a FACScan cell
sorter with excitation at 488 nm (15 mW). Gating was per-
formed for both forward and right-angle scatter, and the
resulting histograms (each containing data from 10,000 cells)
were recorded on a three decade log scale. Evaluation of the
data was done using a Hewlett-Packard 310-based computer
system (CONSORT 30; Becton-Dickinson, San Jose, CA).
Immunohistochemical analysis
Frozen tissue sections (6,um) were fixed with cold acetone for
10 min, and then washed with PBS (pH 7.4) for 20 min. The
sections were preincubated with 0.3% H202 in methanol for
20 min, washed three times with PBS, and then incubated
with 5% normal goat serum in PBS for 30 min. Next the
sections were incubated with 10 pg ml-' ONS-M21 for 2 h at
room temperature (or overnight at 4°C), washed three times
with PBS, and then incubated with biotinylated goat anti-
mouse IgG (Dakopatts, Glostrup, Denmark) for 2 h at room
temperature. After another wash with PBS, sections were
incubated with streptavidin-biotin-peroxidase complex for
30 min at room temperature (Leong & Milios, 1987, Ogawa
et al., 1990; Raymond & Leong, 1990). After a further wash
with PBS, the peroxidase reaction was performed for 5 min
using 0.06% diaminobenzidine with 0.01% H202 in 50 mM
Tris-HCl buffer (pH 7.0). Then the sections were counters-
tained with Mayer's hematoxylin or methyl green. Negative
control sections were incubated with nonimmune mouse
IgG1 (Tago Company, Burlington, CA) instead of ONS-
M21.
Immunoprecipitation
ONS-76 cells were surface-labelled with Na'251 by the
iodogen method, and then lysed with 1.0% Nonidet P-40.
After centrifugation to remove nuclear debris, radiolabelled
lysates were precleared using protein A-Sepharose precoated
with bovine serum albumin, and the incubated with ONS-
M21 coupled to goat anti-mouse IgG1 (Zymed, San Fran-
cisco, CA) and cross-linked to protein A-Sepharose. The
immunoprecipitates were resuspended in Laemmli buffer,
boiled for 5 min, and separated by 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The
dried gels were autoradiographed by exposure to X-ray film
(Fuji X-ray film, RX). A glioblastoma cell line (T98G) and a
neuroblastoma cell line (SK-N-DZ), which were respectively
positive and negative for reaction with ONS-M21, were pro-
cessed in the same manner as controls.
Affinity chromatography
ONS-76 cells were grown to confluence in 100 cm2 dishes.
Approximately 1 x 109 cells were lysed with 0.5% Nonidet
P-40 in Tris buffer as described previously (Wakabayashi et
al., 1988).
Ascites containing ONS-M21 was purified with a protein A
mAb purification kit (Bio-Rad Laboratories, Richmond,
CA). The purified IgG thus obtained was used for subse-
quent conjugation to CNBr-activated sepharose, with 10 mg
of IgG being coupled to I ml of sepharose. Nonidet P-40
extracts from ONS-76 cells were applied to the affinity col-
umn and extensively washed with PBS-phenylmethylsul-
phonylfluoride, after which the antigen was eluted using
glycine hydrochloride buffer (pH 3.0) and was neutralised
with 1.5 M Tris (pH 8.8). The material eluted from the col-
umn was subsequently analysed by SDS-PAGE. Because of
the low protein concentration in the eluate, the gels were
stained with silver.
Results
Expression ofONS-M21 antigen by cultured cell lines
The expression of ONS-M21 antigen by 46 established
human tumour cell lines were tested using flow cytometry
(Table I). The mAb reacted strongly with all of three medul-
loblastoma cell lines and also with two PNET lines and 12
glioma lines (eight glioblastomas, two astrocytomas, one
ependymoma, and one oligodendroglioma) (Figures I and 2).
Extensive screening of ther cell lines, including five neuro-
blastomas, two melanomas, five leukaemias, five small cell
lung cancers, and one rhabdomyosarcoma, showed no reac-
tivity with ONS-M21.
Expression of ONS-M21 antigen byfreshfrozen tissue sections
All three medulloblastomas and three supratentorial
primitive neuroectodermal tumours (SPNETs), as well as 12
out of 13 gliomas (three glioblastomas, five malignant astro-
cytomas, and five astrocytomas) showed strong cell surface
staining by ONS-M21 (Figure 3). In contrast, five neuroblas-
tomas and benign brain tumours (six meningiomas, four
neurinomas, one pituitary adenoma, and one chemodectoma)
showed no reactivity with ONS-M21. Various normal tissues
such as stomach, colon, pancreas, and spleen also showed no
reactivity. The results are summarised in Table II.
Expression ofONS-M21 antigen by peripheral blood cells
The reactivity of ONS-M21 with peripheral blood cells from
five normal individuals was examined by flow cytometry.
CD3-positive, CD1 lb-positive, and CD16-positive cells did
not shown any reactivity with ONS-M21, both by FACS
analysis and also by immunohistochemical staining.
Characterisation ofthe ONS-M21 antigen
For characterisation of the ONS-M21 antigen, ONS-76 cells
were labelled with Na'25 I. After solubilisation of the cells,
the material precipitated by the ONS-M21 mAb was
analysed by SDS-PAGE. A single strong band of about 80
kilodaltons (kDa) was demonstrated in ONS-76 cells and the
same band was weakly present in T98G cells (Figure 4). This
band was not detectable in a cell line that was negative for
ONS-M21 staining (SK-N-DZ).
When the biochemical characteristics of the ONS-M21
antigen were examined by flow cytometry, it was shown to beMOUSE MONOCLONAL ANTIBODY AGAINST MEDULLOBLASTOMA 833
Table I Reactivity of the ONS-M21 mAb with various tumour cell lines as shown by
FACS analysis
Cell lines No. positive/No. tested
Medulloblastoma (ONS-76, 81, Daoy) 3/3
Primitive neuroectodermal tumour (ONS-97, 99) 2/2
Astrocytoma (ONS-6, 9, 11, 12, 20, 23, 75, 77, 10/10
T98G, Al72)
Ependymoma (ONS-16) 1/1
Oligodendroglioma (ONS-21) 1/1
Neuroblastoma (SK-N-DZ, IMR-32, ST, GOTO, NB-1) 0/5
Melanoma (Mewo, G-361) 0/2
Leukaemia (NALM-16, CCRF-CEM, KG-1, ML-2 K562) 0/5
Rhabdomyosarcoma (KYM-1) 0/1
Gastric cancer (NUGC-3a, 4, AZ-521, MKN286TG, 1/5
KATO-3)
Hepatoma (HuH-7, 3N1, HLEa) 1/3
Mammary cancer (MRK-nu-1) 0/1
Small cell lung cancer (OSI, OS2-RA, OS3-R, N231, N857) 0/5
Mouse glioma (203 glioma, RSV-M) 0/2
areactive with ONS-M21.
b
Figure 1 Immunohistochemical staining of ONS-76 cells with the ONS-M21 mAb. a, Positive
ONS-M21 (x 160). b, Negative staining with the control antibody (x 160).
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Figure 2 FACS analysis of the reactivity of ONS-M21 with two medulloblastoma cell lines, ONS-76 and ONS-81. Left: ONS-76
cells. Right: ONS-81 cells. --- reactivity with the negative control antibody. reactivity with ONS-M21.834 S. MORIUCHI et al.
Figure 3 Cryostat sections of medulloblastoma. a, Positive staining of tumour tissue by ONS-M21
with the control antibody (x 160).
Table II Reactivity of the ONS-M21 mAb for various cryostat
tissue specimens by immunohistochemical analysis.
No. positivel
Tissue specimen No. tested
Medulloblastoma 3/3
SPNETa 3/3
Astrocytoma 12/13
(grade 2 5/5)
(grade 3 4/5)
(grade 4 3/3)
Neuroblastoma 0/5
Neurinoma 0/4
Meningioma 0/6
Pituitary adenoma 0/1
Embryonal carcinoma 0/1
Metastatic brain tumourb 0/3
Chemodectoma 0/1
Normal cerebrum 0/4
Normal cerebellum 0/3
Normal spleen 0/1
Normal pancreas 0/1
Normal stomach 0/1
Normal colon 0/2
Reactive astrocytesc 0/1
Foetal braind
cerebrum 0/2
cerebellum 0/2
brain stem 0/1
aSupratentorial primitive neuroectodermal tumour. bl metastatic
adenocarcinoma of the lung and 2 metastatic gastric carcinomas.
Creactive astrocytes found in the resected specimen of an
arteriovenous malformation. dfoetuses of 23 or 32 weeks' gestational
age.
a trypsin-sensitive and neuraminidase-resistant glycoprotein
(Figure 5). Reactivity with ONS-M21 was mildly enhanced
by treatment with neuraminidase.
Purification ofONS-M21 antigenfrom Nonidet P-40 extracts
About 10 ml (4.6 mg ml-') of the Nonidet P-40 extract of
ONS-76 cells was applied to a column of Sepherose 4B
couples with ONS-M21. The column was washed extensively
and then eluted with glycine hydrochloride buffer (pH 3.0).
As shown in Figure 6, purification with the immunoabsor-
KDa
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97.4-
69-
46-
30-
21.5-
14.3-
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Figure 4 SDS-PAGE of the antigen for mAb ONS-M21 on
ONS-76, T98G, or SK-N-DZ cells. Immunoprecipitation of
ONS-M21 and the control antibody with '25I-labelled membrane
extracts of the three cell lines was analysed under reducing condi-
tions. Lane 2, ONS-76 extract incubated with ONS-M21. Lane 3,
T98G extract incubated with ONS-M21. Lane 4, SK-N-DZ ext-
ract incubated with ONS-M21. Lane 5, ONS-76 extract incubated
with nonimmune mouse IgGI antibody. Lanes 2-5 each contain
protein extracted from I x 108 cells. Lane 1, molecular weight
standards; ordinate, molecular weights in thousands.
bent column was highly effective, and most of the protein in
the Nonidet P-40 extracts emerged in the flow-through frac-
tion without being adsorbed. Most of the antigenic activity
was subsequently eluted by the glycine hydrochloride buffer,
and when this purified material was analysed by SDS-PAGE,
a single 80 kDa band was clearly visualised.MOUSE MONOCLONAL ANTIBODY AGAINST MEDULLOBLASTOMA
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Figure 5 Characterisation of the ONS-M21 antigen by flow cytometry. a, ONS-76 cells treated with PBS and incubated with
control antibody. b, ONS-76 cells treated with PBS and incubated with the ONS-M21 mAb. c, ONS-76 cells treated with 0.1%
trypsin and incubated with the ONS-M21 mAb. d, ONS-76 cells treated with 0.1 Uml-' neuraminidase.
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Figure 6 Characterisation of the ONS-M21 antigen purified by
immunoabsorbent chromatography. The material purified on the
immunosorbent column was analysed by SDS-PAGE and silver
staining. Lane 2, sample eluted by glycine hydrochloride buffer,
pH 3.0 (1 gLg). Lane 3, original Nonidet P-40 extract from ONS-
76 cells (2.7 gg). Lane 1, molecular weight standard; ordinate,
molecular weights in thousands.
Discussion
In the present study, the mAb ONS-M21 was raised against
an established medullobastoma cell line (ONS-76). ONS-76
cells exhibit neuronal differentiation by expressing synap-
tophysin, neurofilament protein (200 and 145 kDa), and
neuron-specific enolase (NSE), but retaina feature ofgliomas
by expressing human leukocyte antigen (HLA) DR in res-
ponse to interferon-gamma (Tamura et al., 1989). Most
authors have concluded that medulloblastoma cell lines
exhibit a predominantly neuronal phenotype (Trojanowski et
al., 1987; He et al., 1989; He et al., 1991; Reed et al., 1991).
As far as we know, this study is the first report that medul-
loblastomas may express a neuroectodermal cell surface
antigen shared with gliomas.
Our initial screening suggested that this antibody did not
react with normal human peripheral blood cells, or normal
and foetal human cerebral tissues. Investigation of the reac-
tivity of ONS-M21 with tumours revealed that its antigen was
expressed by medulloblastomas, SPNETs, and gliomas. How-
ever, the antigen was not expressed by other neuroectoder-
mally derived tumours, including neuroblastoma, melanoma,
and chemodectoma. In addition, hematopoietic tumours such
as leukaemia and other brain tumours like meningioma or
neurinomas did not react with ONS-M21. Furthermore,
small cell lung cancer lines which expressed NSE also showed
no reactivity with ONS-M21 (Tanio et al., 1990; Tachibana
et al., 1992). Finally, normal human adult brain tissue and
foetal brain tissue (23 or 32 weeks' gestation) showed no
reactivity with ONS-M21, and neither did reactive astrocytes
surrounding an arteriovenous malformation.
Biochemical studies showed that the ONS-M21 antigen
was a membrane molecule on human medulloblastomas with
a molecular weight of 80 kDa, and was a trypsin-sensitive,
neuraminidase-resistant glycoprotein. Neuraminidase treat-
ment mildly enhanced reactivity with ONS-M21, perhaps
because the epitope became easier for the mAb to recognise
without interference by sugar chains. The presence of this
antigen in Nonidet P-40 extracts from medulloblastoma and
glioma cell lines was confirmed.
In comparison with the previously described mAbs
directed against medulloblastoma, ONS-M21 showed a
different pattern of reactivity. The antigens defined by the
mAbs CNT/2 and ASHE2 are expressed not only by medul-
loblastomas and gliomas, but also by normal brain tissue
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(Jones et al., 1984; Jennings et al., 1989). In addition, the
mAbs UJ127-11, 5A7, FMG25, and M148 are reactive with
medulloblastomas and neuroblastomas, but not with gliomas
(Kemshead et al., 1983; Gross et al., 1986; Gibson et al.,
1987; Takahashi et al., 1990). Furthermore, the mAbs UJ13A
and T-199 stain medulloblastomas, neuroblastomas, and
gliomas, but they also react with normal brain tissue (Allan
et al., 1983; Feickert et al., 1989). In contrast, the mAbs C12
and D12 react with the cytoplasm or cell membranes of
gliomas and medulloblastomas, but not with neuroblastomas
and normal brain tissue (Wikstrand et al., 1986). The
molecular weights of the antigens detected by C12 and D12
are 180 kDa and 88 kDa respectively.
The above findings suggest that the ONS-M21 antigen is a
new tumour associated-antigen which is specifically expressed
on the cell membranes of medulloblastomas, PNETs, and
gliomas.
Bailey and Cushing described medulloblastomas as being
derived from medulloblasts, the precursor cell of neuroblasts
and glioblasts (Bailey & Cushing, 1925). However, most
atuhors have reported that medulloblastomas express only a
neuronal phenotype. In contrast, the results of the present
study indicate that medulloblastomas may share common
neuroectodermal elements with gliomas, or else that medullo-
blastomas may have either a neuronal or a glial phenotype.
Since ONS-M21 reacts with medulloblastomas, PNETs,
and gliomas, it may be useful in their differential diagnosis
from other brain tumours. In addition, the strong reactivity
of ONS-M21 with these brain tumours and its lack of reac-
tivity with normal brain tissue may also allow its clinical
application. Since ONS-M21 is an mAb of the IgGl subclass,
its clinical application for conjugation to drugs, radionu-
clides, or toxins, is theoretically feasible.
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